AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.